22.03
Hims Hers Health Inc stock is traded at $22.03, with a volume of 145.07M.
It is up +40.91% in the last 24 hours and up +14.74% over the past month.
Hims & Hers Health Inc operates telehealth platforms, providing access to treatments for various chronic conditions, including those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. The company connects patients to licensed healthcare professionals who can prescribe medications, with prescriptions fulfilled online through licensed pharmacies. In addition, it offers access to various non-prescription health and wellness products. Through the Hims & Hers mobile applications, the company also offers access to educational programs, wellness content, community support, and other services that promote lifelong health and wellness. Geographically, it derives maximum revenue from the USA.
See More
Previous Close:
$15.74
Open:
$23.215
24h Volume:
145.07M
Relative Volume:
6.00
Market Cap:
$5.03B
Revenue:
$1.78B
Net Income/Loss:
$164.40M
P/E Ratio:
31.93
EPS:
0.69
Net Cash Flow:
$236.51M
1W Performance:
+34.59%
1M Performance:
+14.74%
6M Performance:
-53.59%
1Y Performance:
-38.30%
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
HIMS
Hims Hers Health Inc
|
22.07 | 3.59B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.93 | 56.49B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
119.72 | 51.26B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.19 | 45.79B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.68 | 36.16B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
520.18 | 20.96B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge - Benzinga
Hims and Novo End Feud With Obesity Drug Deal - GuruFocus
Hims & Hers Jumps 47% as Novo Nordisk Weighs New Weight-Loss Drug Partnership - GuruFocus
Hims & Hers, Novo Nordisk Reunite in GLP-1 Deal Weeks After Lawsuit - Athletech News
Hims & Hers: Repartnering With Novo Removes Legal Overhang and Reshapes Weight Loss Segment - Morningstar
Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (13 Ratings) - Benzinga
Hims & Hers Health Inc (HIMS) Shares Up 40.72% on Mar 9 - GuruFocus
Hims & Hers stock: why today's gains are unlikely to be sustainable - TradingView
Hims & Hers Shares Surge on Novo Nordisk Deal Report - GuruFocus
Hims & Hers abandons plan for cheaper Wegovy knockoff after FDA warningLos Angeles Times - Los Angeles Times
Hims shares shoot up after weight-loss drug deal with Novo Nordisk - Financial Times
HIMS Stock Surges Over 38% to New Heights - GuruFocus
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy? - The Motley Fool
Hims & Hers & Novo Nordisk Partner for Ozempic, Wegovy Sales | 2026News and Statistics - IndexBox
Hims & Hers Stock Soars. Its Weight-Loss Drug Battle With Novo Nordisk Takes a Surprising Twist. - Barron's
HIMS Upgraded to Buy by Needham with $30 Target Price | HIMS Sto - GuruFocus
Hims & Hers Stock Jumps on Reports Novo Nordisk Obesity Deal - GuruFocus
Why Hims & Hers Health (HIMS) Stock Is Up Today - Finviz
Novo Nordisk & Hims & Hers Deal: Wegovy, Ozempic Sales on PlatformNews and Statistics - IndexBox
Novo Nordisk drops lawsuit against Hims & Hers over off-brand weight loss medications, enter collaboration - PBS
Hims partners with Novo Nordisk, Live Nation settles antitrust suit - Yahoo Finance UK
Novo, Hims reach deal to sell GLP-1 drugs together - BioPharma Dive
Stock Movers: Hims & Hers Health, Live Nation Entertainment, Brown-Forman - Bloomberg.com
Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform - Yahoo Finance
Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute - Yahoo Finance
Hims & Hers stock jumps after Novo Nordisk drops lawsuit - Yahoo Finance
Novo drops Hims & Hers lawsuit, will sell Wegovy on site - Modern Healthcare
HIMS Stock Eyes Best Day Ever After Dispute Dissolution - Schaeffer's Investment Research
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration - Boston Herald
HIMS Stock Surges Over 37% Amid Market Rally - GuruFocus
Hims & Hers Stock Skyrockets 37% as Novo Nordisk Ends Weight Loss Drug Lawsuit - TIKR.com
Hims Novo Nordisk Obesity Drug Deal Recasts Growth And Valuation Story - Yahoo Finance
Hims & Hers (HIMS) Soars on Novo Nordisk Partnership Announcemen - GuruFocus
Hims & Hers Health (HIMS) Stock Soars Over 45% Following Novo No - GuruFocus
Novo's Quiet Comeback Begins (NYSE:NVO) - Seeking Alpha
Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers - WSJ
Novo Drops Hims & Hers Lawsuit and Will Sell Wegovy on Site - Bloomberg.com
NVO Joins Forces with Hims & Hers to Enhance GLP-1 Treatment Acc - GuruFocus
Hims & Hers Stock Pops on a Deal With Rival Novo Nordisk—What You Need to Know - Investopedia
Hims & Hers stock price is surging today. A surprising deal with Novo Nordisk is the reason why - Fast Company
The Pivot to Legitimacy: Hims & Hers Health (HIMS) Faces a New Era of Personalized Medicine - FinancialContent
ETFs tied to HIMS gain attention as the telehealth stock spikes - Seeking Alpha
Hims shares jump on deal to offer Novo's Wegovy, Ozempic on its platform - MSN
Hims & Hers surges on deal with Novo for weight loss drugs, ending legal feud (HIMS:NYSE) - Seeking Alpha
HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy - Stocktwits
Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers Platform - Yahoo Finance
Hims & Hers partners with Novo Nordisk on weight loss drugs - Investing.com
Morning Market Movers: XENE, HIMS, OLMA, QURE See Big Swings - RTTNews
What’s Happening With HIMS Stock? - Forbes
Hims & Hers Announces Strategic Shift for US Weight Loss Business - HIMS Investor Relations
Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit - Reuters
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):